Catherine S Hwang1, Hsien-Yen Chang, G Caleb Alexander. 1. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
PURPOSE: We quantified the degree to which the August 2010 reformulation of abuse-deterrent OxyContin affected its use, as well as the use of alternative extended-release and immediate-release opioids. METHODS: We used the IMS Health National Prescription Audit, a nationally representative source of prescription activity in the USA, to conduct a segmented time-series analysis of the use of OxyContin and other prescription opioids. Our primary time period of interest was 12 months prior to and following August 2010. We performed model checks and sensitivity analyses, such as adjusting for marketing and promotion, using alternative lag periods, and adding extra observation points. RESULTS: OxyContin sales were similar before and after the August 2010 reformulation, with approximately 550 000 monthly prescriptions. After adjusting for declines in the generic extended-release oxycodone market, the formulation change was associated with a reduction of approximately 18 000 OxyContin prescription sales per month (p = 0.02). This decline corresponded to a change in the annual growth rate of OxyContin use, from 4.9% prior to the reformulation to -23.8% during the year after the reformulation. There were no statistically significant changes associated with the sales of alternative extended-release (p = 0.42) or immediate-release (p = 0.70) opioids. Multiple sensitivity analyses supported these findings and their substantive interpretation. CONCLUSIONS: The market debut of abuse-deterrent OxyContin was associated with declines in its use after accounting for the simultaneous contraction of the generic extended-release oxycodone market. Further scrutiny into the effect of abuse-deterrent formulations on medication use and health outcomes is vital given their popularity in opioid drug development.
PURPOSE: We quantified the degree to which the August 2010 reformulation of abuse-deterrent OxyContin affected its use, as well as the use of alternative extended-release and immediate-release opioids. METHODS: We used the IMS Health National Prescription Audit, a nationally representative source of prescription activity in the USA, to conduct a segmented time-series analysis of the use of OxyContin and other prescription opioids. Our primary time period of interest was 12 months prior to and following August 2010. We performed model checks and sensitivity analyses, such as adjusting for marketing and promotion, using alternative lag periods, and adding extra observation points. RESULTS:OxyContin sales were similar before and after the August 2010 reformulation, with approximately 550 000 monthly prescriptions. After adjusting for declines in the generic extended-release oxycodone market, the formulation change was associated with a reduction of approximately 18 000 OxyContin prescription sales per month (p = 0.02). This decline corresponded to a change in the annual growth rate of OxyContin use, from 4.9% prior to the reformulation to -23.8% during the year after the reformulation. There were no statistically significant changes associated with the sales of alternative extended-release (p = 0.42) or immediate-release (p = 0.70) opioids. Multiple sensitivity analyses supported these findings and their substantive interpretation. CONCLUSIONS: The market debut of abuse-deterrent OxyContin was associated with declines in its use after accounting for the simultaneous contraction of the generic extended-release oxycodone market. Further scrutiny into the effect of abuse-deterrent formulations on medication use and health outcomes is vital given their popularity in opioid drug development.
Authors: Tara Gomes; Andrea Mastorakos; J Michael Paterson; Ingrid Sketris; Patricia Caetano; Simon Greaves; David Henry Journal: CMAJ Open Date: 2017-11-22
Authors: Kara Suvada; Anna Zimmer; Jesse Soodalter; Jimi S Malik; Dio Kavalieratos; Mohammed K Ali Journal: BMJ Open Date: 2022-06-16 Impact factor: 3.006
Authors: Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson Journal: CMAJ Date: 2018-03-26 Impact factor: 8.262
Authors: Alison R Anderson; Jie Deng; Robert S Anthony; Sebastian A Atalla; Todd B Monroe Journal: Crit Care Nurs Clin North Am Date: 2017-09-27 Impact factor: 1.326
Authors: Janetta L Iwanicki; S Geoff Severtson; Heather McDaniel; Andrew Rosenblum; Chunki Fong; Theodore J Cicero; Matthew S Ellis; Steven P Kurtz; Mance E Buttram; Richard C Dart Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Courtney N Maierhofer; Shabbar I Ranapurwala; Bethany L DiPrete; Naoko Fulcher; Christopher L Ringwalt; Paul R Chelminski; Timothy J Ives; Nabarun Dasgupta; Vivian F Go; Brian W Pence Journal: Pain Med Date: 2021-12-11 Impact factor: 3.637